Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer.

Cyclophilin B (CypB) is a 21-kDa protein with peptidyl-prolyl cis-trans isomerase activity that functions as a transcriptional inducer for Stat5 and as a ligand for CD147. To better understand the global function of CypB in breast cancer, T47D cells with a small interfering RNA-mediated knockdown of CypB were generated. Subsequent expression profiling analysis showed that 663 transcripts were regulated by CypB knockdown, and that many of these gene products contributed to cell proliferation, cell motility, and tumorigenesis. Real-time PCR confirmed that STMN3, S100A4, S100A6, c-Myb, estrogen receptor alpha, growth hormone receptor, and progesterone receptor were all down-regulated in si-CypB cells. A linkage analysis of these array data to protein networks resulted in the identification of 27 different protein networks that were impacted by CypB knockdown. Functional assays demonstrated that CypB knockdown also decreased cell growth, proliferation, and motility. Immunohistochemical and immunofluorescent analyses of a matched breast cancer progression tissue microarray that was labeled with an anti-CypB antibody demonstrated a highly significant increase in CypB protein levels as a function of breast cancer progression. Taken together, these results suggest that the enhanced expression of CypB in malignant breast epithelium may contribute to the pathogenesis of this disease through its regulation of the expression of hormone receptors and gene products that are involved in cell proliferation and motility.

[1]  A. Sultan,et al.  Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells , 2005, Oncogene.

[2]  C. Clevenger,et al.  Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter , 2008, BMC biotechnology.

[3]  R. Blamey,et al.  Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. , 1997, The Journal of clinical endocrinology and metabolism.

[4]  R. Gust,et al.  17-β-estradiol inhibits transforming-growth-factor-β-induced MCF-7 cell migration by Smad3-repression , 2006 .

[5]  Kunihiko Kobayashi,et al.  Differential gene expression of S100 protein family in leukocytes from patients with Kawasaki disease , 2005, European Journal of Pediatrics.

[6]  G. Spik,et al.  Evidence that human milk isolated cyclophilin B corresponds to a truncated form. , 1996, Biochimica et biophysica acta.

[7]  N Andrieu,et al.  Strong association between c-myb and oestrogen-receptor expression in human breast cancer. , 1990, Oncogene.

[8]  C. Vanpouille,et al.  Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. , 2007, Glycobiology.

[9]  John E Tomaszewski,et al.  Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma , 2008, Modern Pathology.

[10]  K. Cowan,et al.  Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  R. Morimoto,et al.  Cloning and Subcellular Localization of Human Mitochondrial hsp70 (*) , 1995, The Journal of Biological Chemistry.

[12]  K. Weston.  Reassessing the role of C-MYB in tumorigenesis , 1999, Oncogene.

[13]  R. Wetzker,et al.  Effects of FK506-binding Protein 12 and FK506 on Autophosphorylation of Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[14]  W. Jin,et al.  Extracellular Matrix Metalloproteinase Inducer (CD147) Confers Resistance of Breast Cancer Cells to Anoikis through Inhibition of Bim* , 2006, Journal of Biological Chemistry.

[15]  S. Hankinson,et al.  The role of prolactin in mammary carcinoma. , 2003, Endocrine reviews.

[16]  T Hunter,et al.  Prolyl Isomerases and Nuclear Function , 1998, Cell.

[17]  J. Koblinski,et al.  Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. , 2008, Cancer research.

[18]  W. Huber,et al.  Model-based variance-stabilizing transformation for Illumina microarray data , 2008, Nucleic acids research.

[19]  R. Freedman,et al.  Protein disulphide isomerase and a lumenal cyclophilin-type peptidyl prolyl cis-trans isomerase are in transient contact with secretory proteins during late stages of translocation. , 1995, European journal of biochemistry.

[20]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[21]  G. Spik,et al.  Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies. , 1995, Journal of immunological methods.

[22]  D. Neal,et al.  Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer , 2002, The Journal of pathology.

[23]  J. Mazurier,et al.  Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. , 2008, Experimental cell research.

[24]  P. Rudland,et al.  S100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis , 2004, British Journal of Cancer.

[25]  L. Murphy,et al.  Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. , 1984, Cancer research.

[26]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[27]  J. Tomaszewski,et al.  Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. , 1995, The American journal of pathology.

[28]  P. Furth,et al.  Loss of Stat5a delays mammary cancer progression in a mouse model , 2002, Oncogene.

[29]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[30]  J. Bonneterre,et al.  Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  C. Walsh,et al.  Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Larson,et al.  Regulation of estrogen and progesterone receptor levels in mouse mammary epithelial cells grown in serum-free collagen gel cultures. , 1985, Endocrinology.

[33]  B. Ganter,et al.  Emerging applications of network and pathway analysis in drug discovery and development. , 2008, Current opinion in drug discovery & development.

[34]  J. Xie,et al.  Signal transducer and activator of transcription-5 activation and breast cancer prognosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Leinster,et al.  Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  J. Hiscott,et al.  Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. , 2000, Immunity.

[37]  C. Clevenger,et al.  The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. , 1991 .

[39]  S. Ness,et al.  Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. , 1998, Molecular cell.

[40]  B. Katzenellenbogen,et al.  Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer , 2000, Breast cancer research : BCR.

[41]  B. Teicher,et al.  Identification of genes expressed in malignant cells that promote invasion. , 2003, Cancer research.

[42]  G. Brattsand.  Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors , 2000, British Journal of Cancer.

[43]  A. Nardulli,et al.  Estrogen receptor α and Sp1 regulate progesterone receptor gene expression , 2003, Molecular and Cellular Endocrinology.

[44]  J. Heitman,et al.  Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral achilles heel? , 2005, Molecular cell.

[45]  Margaret Warner,et al.  Estrogen receptors: how do they signal and what are their targets. , 2007, Physiological reviews.

[46]  K. Tang,et al.  Calcyclin (S100A6) regulates pulmonary fibroblast proliferation, morphology, and cytoskeletal organization in vitro , 2003, Journal of cellular biochemistry.

[47]  A. Andreotti,et al.  Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Frasor,et al.  Prolactin regulation of estrogen receptor expression , 2003, Trends in Endocrinology & Metabolism.

[49]  Simon C Barry,et al.  Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells , 2007, Proceedings of the National Academy of Sciences.

[50]  G. Fischer,et al.  The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding vs. catalysis , 1998, FEBS letters.

[51]  Morgan Huse,et al.  Crystal Structure of the Cytoplasmic Domain of the Type I TGF β Receptor in Complex with FKBP12 , 1999, Cell.

[52]  A. Frankfurter,et al.  Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP. , 2003, Genomics.

[53]  Eivind Hovig,et al.  Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma , 1997, International journal of cancer.

[54]  Hengli Tang,et al.  Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro , 2007, Journal of Virology.

[55]  M. Bukrinsky,et al.  CD147 is a signaling receptor for cyclophilin B. , 2001, Biochemical and biophysical research communications.

[56]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[57]  C. Clevenger,et al.  Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. , 2000, Molecular endocrinology.

[58]  C. Clevenger,et al.  Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells , 2007, Oncogene.

[59]  R. Striker,et al.  Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B , 2007, Hepatology.

[60]  L. Murphy,et al.  Cloning and characterization of a cDNA encoding a highly conserved, putative calcium binding protein, identified by an anti-prolactin receptor antiserum. , 1988, The Journal of biological chemistry.

[61]  C. Walsh,et al.  Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  B. Ryffel,et al.  In situ detection of cyclosporin A: evidence for nuclear localization of cyclosporine and cyclophilins. , 1995, Laboratory investigation; a journal of technical methods and pathology.